BR112014013332A2 - composições farmacêutica de 7-(6-(2-hidroxi-propan-2-il)-1-((trans)-4-metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso - Google Patents

composições farmacêutica de 7-(6-(2-hidroxi-propan-2-il)-1-((trans)-4-metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso Download PDF

Info

Publication number: BR112014013332A2
Authority: BR; Brazil
Prior art keywords: methoxycycloexyl; dihydropyrazine; ona; pyrazin; propan
Prior art date: 2011-12-02

Application number

BR112014013332A

Other languages

English (en)

Other versions

BR112014013332B1 (pt

Inventor

Nicole Miklos Amanda

Joubert James Angela

Menon Anil

Joseph Klopfer Kevin

S Assaf Mahmoud

Joseph Connolly Terrence

Wei-Hwa Leong William

Original Assignee

Signal Pharm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-02

Filing date

2012-11-30

Publication date

2017-06-13

2012-11-30 Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc

2017-06-13 Publication of BR112014013332A2 publication Critical patent/BR112014013332A2/pt

2022-09-06 Publication of BR112014013332B1 publication Critical patent/BR112014013332B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Immunology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

BR112014013332-8A 2011-12-02 2012-11-30 Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso BR112014013332B1 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201161566109P	2011-12-02	2011-12-02
US61/566,109		2011-12-02
US201261647288P	2012-05-15	2012-05-15
US61/647,288		2012-05-15
US201261653439P	2012-05-31	2012-05-31
US61/653,439		2012-05-31
US201261670419P	2012-07-11	2012-07-11
US61/670,419		2012-07-11
PCT/US2012/067172 WO2013082344A1 (en)	2011-12-02	2012-11-30	Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use

Publications (2)

Publication Number	Publication Date
BR112014013332A2 true BR112014013332A2 (pt)	2017-06-13
BR112014013332B1 BR112014013332B1 (pt)	2022-09-06

Family

ID=47324465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014013332-8A BR112014013332B1 (pt)	2011-12-02	2012-11-30	Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso

Country Status (23)

Country	Link
US (1)	US9403829B2 (pt)
EP (1)	EP2785325B1 (pt)
JP (2)	JP6076370B2 (pt)
KR (1)	KR102040997B1 (pt)
CN (1)	CN104093398B (pt)
AU (1)	AU2012304276B2 (pt)
BR (1)	BR112014013332B1 (pt)
CA (2)	CA3125862A1 (pt)
CO (1)	CO6990726A2 (pt)
EA (1)	EA026390B1 (pt)
EC (1)	ECSP14007473A (pt)
ES (1)	ES2694413T3 (pt)
IL (1)	IL232827B (pt)
IN (1)	IN2014CN04037A (pt)
MX (1)	MX363034B (pt)
MY (1)	MY169749A (pt)
NI (1)	NI201400052A (pt)
PE (1)	PE20141696A1 (pt)
PH (2)	PH12014501230A1 (pt)
SG (2)	SG11201402766UA (pt)
UA (1)	UA114496C2 (pt)
WO (1)	WO2013082344A1 (pt)
ZA (1)	ZA201403865B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014009755B1 (pt)	2011-10-19	2022-09-13	Signal Pharmaceuticals, Llc	Tratamento de câncer com inibidores de quinase tor
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
NZ630467A (en)	2013-01-16	2017-02-24	Signal Pharm Llc	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
HK1221168A1 (zh) *	2013-04-17	2017-05-26	西格诺药品有限公司	用於治療癌症的包括tor激酶抑制劑和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的組合療法
NZ631082A (en)	2013-04-17	2017-06-30	Signal Pharm Llc	Methods for treating cancer using tor kinase inhibitor combination therapy
KR102221029B1 (ko)	2013-04-17	2021-02-26	시그날 파마소티칼 엘엘씨	디하이드로피라지노-피라진을 사용한 암의 치료
JP2016516815A (ja)	2013-04-17	2016-06-09	シグナルファーマシューティカルズ，エルエルシー	１−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
WO2014172436A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026257B1 (pt)	2013-04-17	2022-12-20	Signal Pharmaceuticals, Llc	Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
TWI604843B (zh)	2013-04-17	2017-11-11	標誌製藥公司	藉二氫吡并吡治療癌症
AU2014254056B2 (en)	2013-04-17	2019-06-06	Signal Pharmaceuticals, Llc	Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
US9604939B2 (en) *	2013-05-29	2017-03-28	Signal Pharmaceuticals, Llc	Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) *	2014-04-16	2015-10-22	Signal Pharmaceuticals, Llc	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) *	2014-04-16	2017-08-01	Signal Pharmaceuticals, Llc	Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017514806A (ja)	2014-04-16	2017-06-08	シグナルファーマシューティカルズ，エルエルシー	Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ629796A (en)	2014-07-14	2015-12-24	Signal Pharm Llc	Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR20170024120A (ko)	2014-07-14	2017-03-06	시그날 파마소티칼 엘엘씨	치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
KR102795129B1 (ko)	2017-06-22	2025-04-15	셀진 코포레이션	B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CN112409399B (zh) *	2019-08-20	2022-06-28	德琪(浙江)医药科技有限公司	一种药物中间体化合物的制备方法
US20220380348A1 (en) *	2019-10-04	2022-12-01	Sumitomo Dainippon Pharma Oncology, Inc.	Axl inhibitor formulations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3507866A (en)	1967-08-08	1970-04-21	Merck & Co Inc	1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en)	1968-11-20	1971-03-02	Merck & Co Inc	Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294837A (en)	1980-03-28	1981-10-13	Sterling Drug Inc.	1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4317909A (en)	1980-03-24	1982-03-02	Sterling Drug Inc.	Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294836A (en)	1980-03-24	1981-10-13	Sterling Drug Inc.	1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en)	1980-03-28	1982-01-05	Sterling Drug Inc.	Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en)	1987-04-21	1987-05-28	Pfizer Ltd	Heterobicyclic quinoline derivatives
JPS63275582A (ja)	1987-05-02	1988-11-14	Naade Kenkyusho:Kk	２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de)	1987-07-10	1988-11-16	Akad Wissenschaften Ddr	Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr)	1989-03-03	1990-09-07	Union Pharma Scient Appl	Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en)	1990-02-28	1990-10-16	Sterling Drug Inc.	Imidazopyridines, their preparation and use
TW274550B (pt)	1992-09-26	1996-04-21	Hoechst Ag
DE19601627A1 (de)	1996-01-18	1997-07-24	Bayer Ag	Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en)	1996-04-09	2000-02-29	Pfizer Inc	Substituted pyridines
NZ503432A (en)	1997-09-26	2002-11-26	Zentaris Gmbh	Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ZA9810490B (en)	1997-12-03	1999-05-20	Dainippon Pharmaceutical Co	2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja)	1999-05-31	2003-05-21	Dainippon Pharmaceut Co Ltd	２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja)	1999-06-02	2006-08-23	大日本住友製薬株式会社	２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja)	2000-09-25	2002-04-05	Mitsubishi Chemicals Corp	リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja)	2000-11-29	2002-06-11	Dainippon Pharmaceut Co Ltd	２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
MXPA03004245A (es)	2000-12-12	2003-09-22	Neurogen Corp	Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas.
WO2002076954A1 (en)	2001-03-23	2002-10-03	Smithkline Beecham Corporation	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
UY27427A1 (es)	2001-09-04	2003-03-31	Boehringer Ingelheim Pharma	Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
JP2005506350A (ja)	2001-10-18	2005-03-03	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
US7247621B2 (en)	2002-04-30	2007-07-24	Valeant Research & Development	Antiviral phosphonate compounds and methods therefor
CN1653077A (zh)	2002-05-06	2005-08-10	健亚生物科技公司	治疗c型肝炎病毒感染的核苷衍生物
US20040204420A1 (en)	2002-08-05	2004-10-14	Rana Tariq M.	Compounds for modulating RNA interference
EP1556053A4 (en)	2002-10-31	2006-04-19	Amgen Inc	ANTI-INFLAMMATORY AGENTS
ATE433967T1 (de)	2003-01-17	2009-07-15	Warner Lambert Co	2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
ATE361924T1 (de)	2003-02-26	2007-06-15	Boehringer Ingelheim Pharma	Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB2400101A (en)	2003-03-28	2004-10-06	Biofocus Discovery Ltd	Compounds capable of binding to the active site of protein kinases
MXPA05011248A (es)	2003-04-23	2005-12-14	Wyeth Corp	Derivados de wortmanina solubles en agua.
ES2586668T5 (es)	2003-05-30	2024-11-12	Gilead Pharmasset Llc	Análogos de nucleósidos fluorados modificados
WO2005013894A2 (en)	2003-06-26	2005-02-17	Merck & Co., Inc.	Benzodiazepine cgrp receptor antagonists
EP1750715A1 (en)	2004-06-04	2007-02-14	Icos Corporation	Methods for treating mast cell disorders
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja)	2004-06-23	2006-01-05	Banyu Pharmaceutical Co., Ltd.	２－アリールプリン誘導体の製造方法
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
EP1796467A4 (en)	2004-09-24	2009-07-01	Janssen Pharmaceutica Nv	INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
BRPI0517272A (pt)	2004-10-29	2008-10-07	Tibotec Pharm Ltd	derivados de pirimidina bicìclicos de inibição de hiv
US7855205B2 (en)	2004-10-29	2010-12-21	Janssen Pharmaceutica Nv	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv)	2004-12-09	2004-12-09	Biovitrum Ab	New compounds
AU2005316668B2 (en)	2004-12-13	2012-09-06	Millennium Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
AU2006215386B2 (en)	2005-02-16	2009-06-11	Astrazeneca Ab	Chemical compounds
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
AU2006217742A1 (en) *	2005-02-25	2006-08-31	Kudos Pharmaceuticals Limited	Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
MX2007012393A (es)	2005-04-05	2008-02-22	Pharmacopeia Inc	Derivados de purina e imidazopiridina para la inmunosupresion.
EA015922B1 (ru) *	2005-11-14	2011-12-30	Ариад Фармасьютикалз, Инк.	ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
US20090281075A1 (en)	2006-02-17	2009-11-12	Pharmacopeia, Inc.	Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2008016669A2 (en)	2006-08-02	2008-02-07	Cytokinetics, Incorporated	Certain chemical entities, compositions and methods
AU2007338601C1 (en)	2006-09-05	2014-07-24	Emory University	Tyrosine kinase inhibitors for prevention or treatment of infection
US20100144738A1 (en)	2006-09-05	2010-06-10	William Bornmann	Inhibitors of c-met and uses thereof
TW200831104A (en)	2006-10-04	2008-08-01	Pharmacopeia Inc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ZA200902382B (en)	2006-10-19	2010-08-25	Signal Pharm Llc	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CN101679432B (zh)	2006-10-19	2015-04-22	西格诺药品有限公司	杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
AU2008345225A1 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
US8110578B2 (en) *	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2379561B1 (en)	2008-11-25	2015-11-04	University Of Rochester	Mlk inhibitors and methods of use
MX341704B (es)	2009-10-26	2016-08-31	Signal Pharm Llc	Métodos de síntesis y purificación de compuestos de heteroarilo.
SG183155A1 (en)	2010-02-03	2012-09-27	Signal Pharm Llc	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

2012
- 2012-11-30 BR BR112014013332-8A patent/BR112014013332B1/pt active IP Right Grant
- 2012-11-30 MX MX2014006590A patent/MX363034B/es unknown
- 2012-11-30 CN CN201280068858.0A patent/CN104093398B/zh active Active
- 2012-11-30 EA EA201491083A patent/EA026390B1/ru not_active IP Right Cessation
- 2012-11-30 UA UAA201407398A patent/UA114496C2/uk unknown
- 2012-11-30 KR KR1020147017858A patent/KR102040997B1/ko active Active
- 2012-11-30 SG SG11201402766UA patent/SG11201402766UA/en unknown
- 2012-11-30 AU AU2012304276A patent/AU2012304276B2/en active Active
- 2012-11-30 PE PE2014000854A patent/PE20141696A1/es not_active Application Discontinuation
- 2012-11-30 CA CA3125862A patent/CA3125862A1/en active Pending
- 2012-11-30 US US13/689,972 patent/US9403829B2/en active Active
- 2012-11-30 SG SG10201604558SA patent/SG10201604558SA/en unknown
- 2012-11-30 EP EP12798565.3A patent/EP2785325B1/en active Active
- 2012-11-30 WO PCT/US2012/067172 patent/WO2013082344A1/en active Application Filing
- 2012-11-30 MY MYPI2014701409A patent/MY169749A/en unknown
- 2012-11-30 JP JP2014544901A patent/JP6076370B2/ja active Active
- 2012-11-30 CA CA2857155A patent/CA2857155C/en active Active
- 2012-11-30 IN IN4037CHN2014 patent/IN2014CN04037A/en unknown
- 2012-11-30 ES ES12798565.3T patent/ES2694413T3/es active Active
2014
- 2014-05-27 ZA ZA2014/03865A patent/ZA201403865B/en unknown
- 2014-05-27 IL IL232827A patent/IL232827B/en active IP Right Grant
- 2014-05-29 NI NI201400052A patent/NI201400052A/es unknown
- 2014-05-30 PH PH12014501230A patent/PH12014501230A1/en unknown
- 2014-06-20 CO CO14134651A patent/CO6990726A2/es unknown
- 2014-07-01 EC ECIEPI20147473A patent/ECSP14007473A/es unknown
2015
- 2015-07-31 PH PH12015501707A patent/PH12015501707B1/en unknown
2016
- 2016-11-02 JP JP2016215572A patent/JP2017048227A/ja active Pending

Also Published As

Publication number	Publication date
PH12014501230B1 (en)	2014-09-08
SG10201604558SA (en)	2016-07-28
ECSP14007473A (es)	2015-11-30
IL232827A0 (en)	2014-07-31
US9403829B2 (en)	2016-08-02
IL232827B (en)	2018-07-31
CA2857155C (en)	2021-09-21
SG11201402766UA (en)	2014-06-27
KR20140098831A (ko)	2014-08-08
JP2015500236A (ja)	2015-01-05
EA026390B1 (ru)	2017-04-28
CO6990726A2 (es)	2014-07-10
EP2785325B1 (en)	2018-08-22
NZ711123A (en)	2016-06-24
PH12014501230A1 (en)	2014-09-08
CN104093398B (zh)	2017-03-15
CN104093398A (zh)	2014-10-08
AU2012304276B2 (en)	2015-01-15
MX2014006590A (es)	2014-07-11
PH12015501707A1 (en)	2017-01-16
EP2785325A1 (en)	2014-10-08
NZ625511A (en)	2016-03-31
PH12015501707B1 (en)	2017-01-16
EA201491083A1 (ru)	2014-11-28
HK1202052A1 (en)	2015-09-18
CA3125862A1 (en)	2013-06-06
MX363034B (es)	2019-03-06
CA2857155A1 (en)	2013-06-06
JP2017048227A (ja)	2017-03-09
ZA201403865B (en)	2015-11-25
EA201491083A8 (ru)	2015-02-27
IN2014CN04037A (pt)	2015-10-23
US20130142873A1 (en)	2013-06-06
KR102040997B1 (ko)	2019-11-27
BR112014013332B1 (pt)	2022-09-06
JP6076370B2 (ja)	2017-02-08
WO2013082344A1 (en)	2013-06-06
AU2012304276A1 (en)	2013-06-20
MY169749A (en)	2019-05-15
UA114496C2 (uk)	2017-06-26
NI201400052A (es)	2015-01-12
ES2694413T3 (es)	2018-12-20
PE20141696A1 (es)	2014-11-08

Publication	Publication Date	Title
BR112014013332A2 (pt)	2017-06-13	composições farmacêutica de 7-(6-(2-hidroxi-propan-2-il)-1-((trans)-4-metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
SMT201600155B (it)	2016-07-01	Pirazolo[i, 5-a]pirimidine e -triazine come agenti antivirali
IL230981A0 (en)	2014-03-31	Derivatives of 5 - fluoro - 4 - imino - 3 - (converted) - 3, 4 - dihydropyrimidine - 2 - (1h) - one
ZA201402905B (en)	2016-01-27	[1,2,3]triazolo [4,5-d]pyrimidine derivatives as agonist of the cannabinoid receptor 2
IL232570A0 (en)	2014-06-30	Bicyclic derivatives of dihydroisoquinoline-1-one
IL230874A0 (en)	2014-03-31	History of new bicyclic dihydroinolin-2-ones
IL240877A0 (en)	2015-10-29	History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
IL243092A0 (en)	2016-02-01	New triazolo[d–4,5]pyrimidine histories
EP2720699A4 (en)	2015-04-29	ADMINISTRATION OF BENZODIAZEPINE
ZA201309187B (en)	2014-08-27	Pyridin-2(1h)-one derivatives as jak inhibitors
CO6811848A2 (es)	2013-12-16	Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
ZA201403441B (en)	2015-08-26	[1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
AP2013007147A0 (en)	2013-09-30	Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
EP2739627A4 (en)	2015-01-21	2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
PL2694513T3 (pl)	2015-06-30	Pochodne pirazolopirymidynowe
ZA201406323B (en)	2016-08-31	Triazolo[4,5-d]pyrimidine derivatives
IL232061A (en)	2016-04-21	The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use
CR20140260A (es)	2014-08-25	Composiciones farmaceuticas de 7-(6- (2-hidroxi propan -2-il) piridin -3-il) -1- ((trans) -4-metoxiciclohexil ) -3, 4- dihidropiracino [2,3-b] piracin-2 (1h) -ona, una forma solida de las mismas y metodos de su uso
TH1501006326A (th)	2017-10-05	สูตรผสมทางเภสัชกรรม, กระบวนการ, รูปแบบของแข็ง และวิธีของการใช้ที่เกี่ยวข้องกับ 1-เอธิล-7-(2-เมธิล-6-(1h-1,2,4-ไทรอะโซล-3-อิล) ไพริดิน-3-อิล)-3,4-ไดไฮโดรไพราซิโน[2,3-b]ไพราซิน-2(1h)-โอน
HK1196814A (en)	2014-12-24	Pyridin-2(1h)-one derivatives as jak inhibitors

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-08-13	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-11-30	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-03-22	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-07-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-09-06	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2012, OBSERVADAS AS CONDICOES LEGAIS